Synaptic Systems

Cat. No.: 177 003

Amount: 50 µg

Price: $375.00

Cat. No. 177 003	50 µg specific antibody, lyophilized. Affinity purified with the immunogen. Albumin was added for stabilization. For reconstitution add 50 µl H₂O to get a 1mg/ml solution in PBS. Then aliquot and store at -20°C to -80°C until use. Antibodies should be stored at +4°C when still lyophilized. Do not freeze!
Applications	WB: 1 : 1000 (AP staining) (see remarks) gallery IP: not tested yet ICC: not tested yet IHC: not tested yet IHC-P: not tested yet Western blot (WB); separation of proteins by PAGE and subsequent transfer to a membrane. Detection of target molecules is carried out with antibodies. Some antibodies require special sample preparation steps. For details, please refer to the “Remarks” section. Immunoprecipitation (IP); Immunoisolation or pulldown of a target molecule using an antibody. For details and product specific hints, please refer to the ”Remarks” section. Immunocytochemistry (ICC) on 4% PFA fixed cells. Immunoreactivity is usually revealed by fluorescence. Some antibodies require special fixation methods. For details, please refer to the “Remarks” section. Immunohistochemistry (IHC) on 4% PFA perfusion fixed tissue with 24h PFA post fixation. Immunoreactivity is usually revealed by fluorescence or a chromogenic substrate. Some antibodies require special fixation methods or antigen retrieval steps. For details, please refer to the ”Remarks” section. Immunohistochemistry (IHC-P) of formalin fixed, paraffin embedded (FFPE) tissue (some antibodies require special antigen retrieval steps, please refer to the ”Remarks” section). Immunoreactivity is usually revealed by fluorescence or a chromogenic substrate.
Immunogen	Recombinant protein corresponding to AA 363 to 595 from mouse P2X7 (UniProt Id: Q9Z1M0)
Reactivity	Reacts with: rat (Q64663), mouse (Q9Z1M0). Other species not tested yet.
Specificity	K.O. validated PubMed: 25700737
Remarks	Detects mouse protein with higher sensitivity. WB: This antibody detects an additional band at 30 kDa of unknown identity.
Data sheet	177_003.pdf

References for P2X7 - 177 003

P2X7 Purinoceptor Affects Ectopic Calcification of Dystrophic Muscles.
Rumney RMH, Róg J, Chira N, Kao AP, Al-Khalidi R, Górecki DC
Frontiers in pharmacology (2022) 13: 935804. 177 003 WB, ICC; KO verified; tested species: mouse

iTRAQ-based proteomics implies inflammasome pathway activation in the prefrontal cortex of CSDS mice may influence resilience and susceptibility.
Lan T, Bai M, Chen X, Wang Y, Li Y, Tian Y, He Y, Wu Z, Yu H, Chen Z, Chen C, et al.
Life sciences (2020) 262: 118501. 177 003 WB; tested species: mouse

Re-evaluation of neuronal P2X7 expression using novel mouse models and a P2X7-specific nanobody.
Kaczmarek-Hajek K, Zhang J, Kopp R, Grosche A, Rissiek B, Saul A, Bruzzone S, Engel T, Jooss T, Krautloher A, Schuster S, et al.
eLife (2018) 7: . 177 003 WB, IHC; tested species: mouse

Sustained activation of P2X7 induces MMP-2-evoked cleavage and functional purinoceptor inhibition.
Young CNJ, Chira N, Róg J, Al-Khalidi R, Benard M, Galas L, Chan P, Vaudry D, Zablocki K, Górecki DC
Journal of molecular cell biology (2017) : . 177 003 WB; tested species: mouse

A novel mechanism of autophagic cell death in dystrophic muscle regulated by P2RX7 receptor large-pore formation and HSP90.
Young CN, Sinadinos A, Lefebvre A, Chan P, Arkle S, Vaudry D, Gorecki DC
Autophagy (2015) 111: 113-30. 177 003 WB; KO verified

P2RX7 purinoceptor: a therapeutic target for ameliorating the symptoms of duchenne muscular dystrophy.
Sinadinos A, Young CN, Al-Khalidi R, Teti A, Kalinski P, Mohamad S, Floriot L, Henry T, Tozzi G, Jiang T, Wurtz O, et al.
PLoS medicine (2015) 1210: e1001888. 177 003 ICC, WB

Expression, assembly and function of novel C-terminal truncated variants of the mouse P2X7 receptor: re-evaluation of P2X7 knockouts.
Masin M, Young C, Lim K, Barnes SJ, Xu XJ, Marschall V, Brutkowski W, Mooney ER, Gorecki DC, Murrell-Lagnado R
British journal of pharmacology (2012) 1654: 978-93. 177 003 WB

P2X7 purinoceptor alterations in dystrophic mdx mouse muscles: relationship to pathology and potential target for treatment.
Young CN, Brutkowski W, Lien CF, Arkle S, Lochmüller H, Zabłocki K, Górecki DC
Journal of cellular and molecular medicine (2012) 165: 1026-37. 177 003 WB

Cat. No.: 177 003

Amount: 50 µg

Price: $375.00

Background

Neurotransmitters are released from synaptic vesicles into the synaptic cleft where they can bind to neurotransmitter receptors located in the plasma membrane. Purines can act as neurotransmitters and the corresponding receptors can be subdivided into two families: P1 receptors are sensitive to adenosine while P2 receptors are triggered by ATP.
The P2 receptor family is composed of two major groups, the metabotrophic G protein coupled P2Y receptors and the ionotrophic ATP-gated cation channels receptors P2X. Seven P2X receptors have been identified so far which all share a similar transmembrane topology. They consist of N- and C-termini facing the cytoplasm, two transmembrane spanning domains and a large extracellular loop. Compared to P2X1-6 P2X7 has a much longer cytoplasmic C-terminal tail. The P2X1-7 receptors are able to form hetero- or homo-multimers. The tissue distribution and function of P2X7 is still under discussion.

1 ) Raouf R et al., Neuropharmacology (2007)
2 ) Cheung KK et al., Pancreas (2007)
3 ) Gunosewoyo H et al., Curr. Med. Chem. (2007)
4 ) Lee DH et al., Pancreas (2007)
5 ) Bennett MR et al., Aust N Z J Psychiatry (2007)
6 ) Barth K et al., FEBS J. (2007)
7 ) Papp L et al., Biochem. Biophys. Res. Commun. (2007)
8 ) Sperlágh B et al., Prog. Neurobiol. (2006)
9 ) Chessell IP et al., Pain (2005)
10 ) Ireland MF et al., Neuroscience (2004)

Protocols

P2X7 antibody - 177 003 K.O.

References for P2X7 - 177 003